Skip to main content

Table 1 Characteristics of patients

From: Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae

Characteristic

Total

Complete cohort (N = 180)

Cohort adjusted by PSMa

BLICs

Carbapenems

P

BLICs

Carbapenems

P

N (%)

180

N = 114 (63.3%)

N = 66 (36.7%)

 

N = 63 (59.4%)

N = 43 (40.6%)

 

Age, years

 Mean (SD)

59.3 (13.1)

61.7 (12.4)

55.2 (13.3)

0.001

58.2 (12.3)

55.7 (11.9)

0.469

Sex, N (%)

 Male

91 (50.6)

58 (50.9)

33 (50.0)

0.910

30(47.6)

22 (51.2)

0.720

 Female

89 (49.4)

56 (49.1)

33 (50.0)

 

33 (52.4)

21 (48.8)

 

Acquisition, N (%)

 Hospital-acquired

117 (65.0)

71 (62.3)

46 (69.7)

0.315

41 (65.1)

32 (74.4)

0.308

 Community-associated

63 (35.0)

43 (37.7)

20 (30.3)

 

22 (34.9)

11 (25.6)

 

Length, median (IQR)

 Length of hospital stay

20.5 (12–30)

18 (11–28)

24 (14–32)

0.016

20 (11–29)

25 (14–32)

0.055

Severity of condition, median (IQR)

 aCCI

3 (2–5)

4 (2–6)

3 (2–4.25)

0.036

3 (2–5)

3 (2–4)

0.797

 Pitt bacteraemia score

1 (0–2.75)

1 (0–2)

2 (1–4)

0.000

1 (0–2)

1 (0–2.5)

0.995

 SOFA score

3 (2–6)

3 (1–5)

5 (2.75–9)

0.000

4 (2–6)

3 (1.3–6)

0.517

Underlying diseases, N (%)

 Immune compromise

35 (19.4)

15 (13.2)

20 (30.3)

0.005

13 (20.6)

13 (30.2)

0.259

 Leukaemia

13 (7.2)

3 (2.6)

10 (15.2)

0.002

3 (4.8)

7 (16.3)

0.086

 Arrhythmia

16 (8.9)

11 (9.6)

5 (7.6)

0.638

5 (7.9)

3 (7.0)

1.000

 Hypertension

42 (23.2)

27 (23.7)

15 (22.7)

0.884

12 (19.0)

7 (16.3)

0.970

 Diabetes

20 (11.1)

14 (12.3)

6 (9.1)

0.512

6 (9.5)

2 (4.7)

0.469

 Hypoproteinaemia

47 (26.1)

32 (28.1)

15 (22.7)

0.432

16 (25.4)

9 (20.9)

0.820

Bacteria, N (%)

   

0.448

  

0.778

 Escherichia coli

147 (81.7)

95 (83.3)

52 (78.8)

 

54 (85.7)

36 (83.7)

 

 Klebsiella pneumoniae

33 (18.3)

19 (16.7)

14 (21.2)

 

9 (14.3)

7 (16.3)

 

Empirical treatment, N (%)

   

0.268

  

0.154

 Appropriate

159 (88.3)

103(90.4)

56 (84.8)

 

60 (95.2)

37 (86.0)

 

 Inappropriate

21 (11.7)

11 (9.6)

10 (15.2)

 

3 (4.8)

6 (14.0)

 
  1. aAdjustment using propensity score matching, covariates including age, length of hospital stay, aCCI, Pitt bacteraemia score, SOFA score, immune compromise, and leukaemia
Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us